<DOC>
	<DOCNO>NCT00712504</DOCNO>
	<brief_summary>This study determine maximum tolerate dose safety SU011248 ( sunitinib malate , SUTENT ) combination docetaxel ( Taxotere ) . Several dose regimen test patient advance solid tumor , include non small cell lung cancer .</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Advanced solid tumor malignancy ECOG 0 1 Prior treatment highdose chemotherapy require stem cell rescue Prior irradiation â‰¥25 % bone marrow ( e.g . whole pelvis=25 % ) Patients centrally locate lung lesion unless recently treat radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>advanced solid tumor , non small cell lung cancer , pulmonary neoplasm , sunitinib ( SUTENT ) , docetaxel ( Taxotere ) , Angiogenesis Inhibitors</keyword>
</DOC>